Insider Selling: CeriBell (NASDAQ:CBLL) Director Sells $101,255.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Joseph Michael Taylor sold 5,500 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $18.41, for a total value of $101,255.00. Following the completion of the transaction, the director directly owned 61,573 shares of the company’s stock, valued at approximately $1,133,558.93. This trade represents a 8.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

CeriBell Stock Performance

CeriBell stock opened at $17.28 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.01. The stock has a fifty day moving average price of $18.95 and a two-hundred day moving average price of $19.72. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $24.33. The firm has a market capitalization of $655.60 million, a P/E ratio of -10.60 and a beta of 0.84.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The company had revenue of $26.49 million for the quarter, compared to analyst estimates of $26.09 million. As a group, analysts anticipate that CeriBell, Inc. will post -1.69 EPS for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio bought a new position in CeriBell during the first quarter worth about $27,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of CeriBell during the 3rd quarter valued at about $33,000. CWM LLC lifted its holdings in shares of CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after purchasing an additional 1,697 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after purchasing an additional 1,801 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Weiss Ratings lowered CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, June 12th. Canaccord Genuity Group lowered their target price on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $22.20.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.